Objective: Meta analysis was used to explore the efficacy and safety of Sintilimab in the treatment of cancer.Methods: The databases of CNKI, VIP, Wanfang Data, PubMed, ScienceDirect, the Cochrane Library and EMBASE were searched by computer to collect the randomized controlled trials published as of March 2022. The retrieval work was completed by two researchers alone. They screened the literature and extracted the data according to the nanodischarge standard, using Revman 5.4 software. The included studies were statistically analyzed.Results: Six RCTs were included in this study, including 1,048 cases of Sintilimab and 711 cases of other anticancer drugs. Compared with the control group, the overall survival (HR = 1.64, 95% CI: 1.35–1.99, p < 0.00001) and progression free survival (HR = 1.89, 95% CI: 1.59–2.25, p < 0.00001) of cancer treated with Sintilimab were longer and more effective. Moreover, the risk ratio of any grade of adverse reactions (HR = 0.87, 95% CI: 0.74–1.03, p = 0.11) and above grade III adverse reactions (HR = 0.84, 95% CI: 0.67–1.06, p = 0.14) in the treatment of cancer with Sintilimab was lower and the safety was better.Conclusion: Compared with non-Sintilimab group, Sintilimab treatment can improve the clinical efficacy of tumor patients and has a lower incidence of adverse reactions. This treatment may be a promising treatment for cancer patients.

ObjectiveMeta analysis was used to compare the efficacy and safety of immune checkpoint inhibitor and docetaxel in the treatment of non-small cell lung cancer.MethodsCNKI, CBM, PubMed, EMBASE, Cochrane Library, web of science and other databases were searched by computer, and the randomized controlled trials of immune checkpoint inhibitors and docetaxel in the treatment of NSCLC published as of February 2022 were collected. Two researchers searched independently, screened the literature and extracted the data according to the nanodischarge criteria, and used Revman5.4. The included studies were statistically analyzed, and publication bias was analyzed with Egger test in Stata12.ResultsA total of 8 RCTs were included, including 2444 cases treated with immune checkpoint inhibitors and 2097 cases treated with docetaxel. Compared with docetaxel, the overall survival (HR = 1.40, 95%CI: 1.30-1.50, P < 0.00001) and progression free survival (HR = 1.22, 95%CI: 1.13-1.32, P < 0.00001) of NSCLC treated with ICIs were longer. The risk ratio of any grade of adverse reactions (HR = 0.41, 95%CI: 0.32-0.52, P < 0.00001) and above grade III adverse reactions (HR = 0.27, 95%CI: 0.18-0.41, P < 0.00001) in the treatment of NSCLC with ICIs was lower. There was no publication bias in Egger test.ConclusionCompared with docetaxel, immune checkpoint inhibitor treatment can improve the clinical efficacy of NSCLC patients and has a lower incidence of adverse reactions. This treatment may be a promising treatment for NSCLC patients.

Flexible job shops motivated by small batches and multiple orders require the collaboration of machines and automated guided vehicles (AGVs) scheduling to boost shop floor flexibility and productivity. The joint scheduling of machines and AGVs can better achieve global optimization. However, joint scheduling requires two NP hard problems to be solved simultaneously. Therefore, this paper employs a multi-AGV flexible job shop scheduling problem (MA-FJSP) with an effective hybrid algorithm. First of all, a model is established with the objectives of minimizing the makespan, the total AGV running time and the total machine load. To solve the MA-FJSP, high-quality initialization methods and improved elite strategies are designed to improve global convergence in the proposed algorithm. In addition, a problem-knowledge-based neighborhood search is integrated to improve its exploitation capability. At last, a series of comparative experimental studies were performed to exam the effectiveness of the improved algorithm. The results demonstrate that the solutions gained by the proposed algorithm perform well in respect of convergence, diversity and distribution.